AUTHORS
Paolo Strati, MD, Lei Feng, MS2, Yiqian Gu3, Sairah Ahmed, MD4, Ayushi Chauhan, MD5, Ranjit Nair, MD6, Luis E. Fayad, MD7, Luis Malpica, MD8, Laura Ebarle, NP9, Laurel Deaton10, Barbara Averill11, Elizabeth McChesney12, Jared Henderson, PhD13, Daniela Duenas14, Cara Haymaker15, Sattva S Neelapu Sr, MD16, Simona Colla, PhD17, Natthakan Thongon, PhD18
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, United States
2 The University of Texas MD Anderson Cancer Center, Houston, United States
3 The University of Texas MD Anderson Cancer Center, Houston, United States
4 The University of Texas MD Anderson Cancer Center, Houston, United States
5 The University of Texas MD Anderson Cancer Center, Houston, United States
6 The University of Texas MD Anderson Cancer Center, Houston, United States
7 The University of Texas MD Anderson Cancer Center, Houston, United States
8 The University of Texas MD Anderson Cancer Center, Houston, United States
9 The University of Texas MD Anderson Cancer Center, Houston, United States
10 The University of Texas MD Anderson Cancer Center, Houston, United States
11 The University of Texas MD Anderson Cancer Center, Houston, United States
12 The University of Texas MD Anderson Cancer Center, Houston, United States
13 The University of Texas MD Anderson Cancer Center, Houston, United States
14 The University of Texas MD Anderson Cancer Center, Houston, United States
15 The University of Texas MD Anderson Cancer Center, Houston, United States
16 The University of Texas MD Anderson Cancer Center, Houston, United States
17 The University of Texas MD Anderson Cancer Center, Houston, United States
18 The University of Texas MD Anderson Cancer Center, Houston, United States
ABSTRACT
Introduction. Prolonged cytopenia (PC), defined as grade (G) 3 or higher neutropenia, anemia and/or thrombocytopenia persistent beyond 30 days after CAR T-cell infusion, is observed in about 30% of patients with B-cell lymphoma and is associated with shorter survival. Single-cell RNA-sequencing analysis (scRNA-seq) of bone marrow (BM) samples has identified an oligoclonal CD8+ T-cell population expressing high interferon (IFN)-gamma (γ) and hematopoietic stem cells expressing IFN-γ response signatures in patients with PC. Emapalumab is a fully human IgG1 monoclonal antibody that binds free and receptor-bound IFN-γ. Pre-clinical models show that emapalumab does not compromise CAR T-cell function in hematological malignancies, and its use at low doses has shown to be safe in patients treated with CAR T-cell therapy.
Methods. This is a phase 2 study investigating the safety and efficacy of emapalumab for the treatment of PC in patients with relapsed refractory large B-cell lymphoma (LBCL) and follicular lymphoma (FL) treated with standard of care autologous anti-CD19 CAR T-cell therapy. Patients with G3-4 cytopenia present before initiation of lymphodepleting chemotherapy and those with alternative etiologies of cytopenia were excluded. Emapalumab was administered intravenously, on day 1 of a 4-week cycle, at 2 dose levels (1 and 3 mg/Kg), for 1 cycle. One additional cycle was allowed in case of improvement to cytopenia grade 0-2 lasting for less than 4 weeks (partial hematological response or PHR). The primary efficacy endpoint was complete hematological response (CHR), defined as improvement to cytopenia grade 0-2 lasting for longer than 4 weeks, and the Simon’s optimal two-stage design was used. BM biopsies were collected before initiation of treatment and at the end of each cycle and evaluated by scRNA-seq.
Results. We report here final clinical and translational results for the 5 patients treated at 1 mg/Kg. Three were female, median age was 55 years (range 26-72), 4 had LBCL (1 FL), and all had received axi-cel. Four patients had received CAR T-cell therapy in third line or beyond (1 in second line), and all were in complete response at time of study start. Before initiation of emapalumab, 2 patients required red blood cell (RBC) transfusions (2 and 8 total, each), 1 platelet transfusion (26 total), 4 growth factor (GF) support (with a median of 9 injections each, range 9-38), and 4 had been hospitalized (a median of 1 time each, range 1-4). At time of emapalumab initiation, median absolute neutrophil count was 0.22 K/uL (range, 0.07-1.1), median hemoglobin was 10.7 g/dL (range, 8.6-12.6) and median platelet count was 114 K/uL (range, 2-213), with a median BM cellularity of 5% (range, 5-40). Two patients received 1 cycle, and 3 patients received 2 cycles. Four patients responded, 2 with a CHR (1 achieved after 1 cycle, 1 after 2 cycles) and 2 with a PHR (both after 2 cycles). After completion of treatment, 1 patient [the non-responder [NR]) required 3 RBC and 9 platelet transfusions, the median number of GF injections was 2 (range, 1-15), and 2 patients were hospitalized (1 and 2 times, each). Of the 2 patients in CHR, 1 (who received 2 cycles) remains in CHR after 18 months and 1 (who received 1 cycle) experienced a hematological relapse after 2 months.
Differential gene expression analysis by scRNA-seq was performed in CD4⁺ and CD8⁺ T-cell populations. Patients in CHR exhibited at baseline significantly decreased expression of the IFN-γ response gene signature compared with those in PHR and NR. Sequential analyses demonstrated suppression of the IFN-γ response gene signature in both CD4⁺ and CD8⁺ T-cell populations following emapalumab treatment in all patients, regardless of clinical response. However, post-treatment gene set enrichment analysis revealed increased TNF-α signaling via NF-κB and inflammatory response pathway enrichment in patients in CHR, not observed in those in PHR or NR.
Conclusion. Low doses of emapalumab are safe and show promising initial efficacy for the treatment of PC in patients with B-cell lymphoma. While emapalumab effectively suppresses IFN-γ-driven transcriptional programs in all patients, clinical response associates with preservation of broader immune activation pathways, including TNF-α/NF-κB and inflammatory signaling. Per Simon’s optimal two-stage design, as less than 3 out of 5 patients achieved a CHR, 5 additional patients will be treated at the next dose level (3 mg/Kg).
DISCLOSURES
Paolo Strati, MD: Sobi, AstraZeneca-Acerta, ALX Oncology, and ADC Therapeutics - Research Funding; Roche-Genentech, Abbvie-Genmab, Ipsen, Kite/Gilead, Novartis, Incyte, Lilly, AstraZeneca-Acerta, BeOne, ADC Therapeutics, Merck - Consultancy (Includes expert testimony)